Number of anti‐VEGF injections · people with neovascular AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants experiencing conjunctival injection (redness) at 4–6 weeks · Demodex blepharitis
1 finding from 1 review
Number of kidneys with temporary renal dilatation after injection · primary VUR
Macroplastique may leads to higher number of kidneys with temporary renal dilatation after injection compared with dextranomer/hyaluronic acid polymer (Deflux) to correct… (low certainty).
1 finding from 1 review
Adherence to method use as indicated by on‐time injections overall · Women of reproductive age seeking to avoid pregnancy
Reminders (+/‐ educational information) showed no clear difference in adherence to method use as indicated by on‐time injections overall compared with usual family planning care (low certainty).
1 finding from 1 review
Adverse effects after treatment initiation: injection site reactions, neutropenia, infections, demyelinating disease, heart failure, malignancy, and induction of autoimmunity. · children diagnosed with Kawasaki disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prostatitis symptoms Subgroup: Intraprostatic injection, participants age > 50 years old, basal NIH‐CPSI score > 30 · participants with chronic prostatitis/chronic pelvic pain syndrome
1 finding from 1 review
Prostatitis symptoms Subgroup: Pelvic floor muscles injection, participants age < 50 years old, basal NIH‐CPSI score < 30 · participants with chronic prostatitis/chronic pelvic pain syndrome
1 finding from 1 review
Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events at 15‐day · 10‐ to 26‐year‐old males
Three doses HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with control (high certainty).
1 finding from 1 review
Overall local/injection site adverse events at 15‐day · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review
Overall local/injection site adverse events · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Swelling at injection site after Vi‐rEPA (dose 2) · adults and children of 2 years of age and older
Vi‐rEPA vaccine (2 doses) probably leads to higher swelling at injection site after Vi‐rEPA (dose 2) compared with control (moderate certainty).
1 finding from 1 review
Local effects at injection site · COPD
Influenza vaccine may leads to higher local effects at injection site compared with placebo (low certainty).
1 finding from 1 review
Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) showed no clear difference in global state: non‐responders to the first injection compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (low certainty).
1 finding from 1 review
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes repeated need for tranquillisation ‐ needing additional injections… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower global state: non‐responders to the first injection compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes repeated need for tranquillisation ‐ needing additional injections… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Intervention not reported
Mode 1: Anterior sub‐Tenon injections (subconjunctival) · participants undergoing cataract surgery
1 finding from 1 review
no estimate extracted
77015 participants
Moderate
Intervention not reported
Mode 2: Posterior sub‐Tenon injections (retrobulbar) · participants undergoing cataract surgery
1 finding from 1 review
no estimate extracted
77015 participants
Moderate
Repeated need for rapid tranquillisation ‐ needing additional injection during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for rapid tranquillisation ‐ needing additional… compared with COMBINATIONS: b. HALOPERIDOL + LORAZEPAM (very low certainty).
1 finding from 1 review